The present application discloses variants of Pertuzumab. In particular, itdiscloses: an unpairedcysteine variant comprising Cys23/Cys88 unpaired cysteines in one or bothvariable light domainsof Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS)of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. Theapplicationfurther discloses the isolated variants, compositions, pharmaceuticalcompositions, and articles ofmanufacture comprising the variants, as well as methods of making andcharacterizing the variantsand compositions thereof.